Posted by Michael Wonder on 15 Jan 2020
Proposal to fund betamethasone dipropionate with calcipotriol (Enstilar) foam spray for psoriasis
15 January 2020 - PHARMAC is seeking feedback on a proposal to fund a new topical psoriasis medicine, betamethasone dipropionate with calcipotriol foam spray (Enstilar) from 1 April 2020, through a provisional agreement with Leo Pharma.
The proposal also includes changes to pack sizes and prices for the following currently funded medicines:
- Calcipotriol ointment 50 mcg per g (Daivonex) – 120 g pack would replace 100 g pack from 1 July 2020
- Sodium fusidate [fusidic acid] 250 mg tablets (Fucidin) – 36 tablet pack would replace the 12 tablet pack from 1 December 2020
- Hydrocortisone butyrate lipocream 0.1% (Locoid Lipocream) – 100 g pack would remain listed and 30 g pack would be delisted.
